E85.8 Other amyloidosis

Name of the Condition

• Other amyloidosis
• ICD-10 Code: E85.8

Summary

Other amyloidosis refers to amyloidosis types not classified under more specific subcategories. It involves the abnormal deposition of amyloid proteins in tissues and organs, which can disrupt normal function. The condition may affect various body systems, including the heart, kidneys, liver, or other organs, depending on the underlying cause and protein type.

Causes

The cause of other amyloidosis varies by subtype. It may result from genetic mutations, chronic inflammatory conditions, or as a secondary complication of other diseases. In some cases, the underlying cause remains unknown, and the specific amyloid protein involved determines the clinical presentation.

Risk Factors

• Family history of amyloidosis or related genetic disorders.
• Chronic inflammatory diseases (e.g., rheumatoid arthritis).
• Age (more common in older adults).
• Long-term dialysis treatment.
• Certain cancers, such as multiple myeloma.
• Prior organ transplantation.

Symptoms

• Fatigue and unexplained weight loss.
• Swelling in the ankles, legs, or abdomen.
• Numbness or tingling in the hands or feet.
• Shortness of breath or heart palpitations.
• Kidney dysfunction or proteinuria.
• Gastrointestinal symptoms like diarrhea or constipation.
• Liver enlargement or abnormal liver function tests.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and tissue biopsy. Biopsy samples are stained with Congo red to confirm amyloid deposits. Additional tests may include imaging studies (e.g., echocardiogram) to assess organ involvement and genetic testing to identify underlying causes.

Treatment Options

Treatment focuses on managing symptoms, reducing amyloid production, and supporting organ function. Options may include medications to target the underlying cause, organ-specific therapies, and in some cases, organ transplantation. Supportive care, such as diuretics for fluid retention or pain management, is also common.

Prognosis and Follow-Up

Prognosis depends on the type of amyloidosis, organs involved, and response to treatment. Regular follow-up is essential to monitor organ function and adjust therapies. Early diagnosis and intervention can improve outcomes, but some subtypes may have a progressive course.

Complications

• Organ failure (e.g., heart, kidney, or liver failure).
• Nerve damage leading to sensory or motor deficits.
• Increased risk of infections.
• Malnutrition due to gastrointestinal involvement.
• Blood clots or bleeding disorders.

Lifestyle & Prevention

• Maintain a balanced diet to support organ health.
• Avoid smoking and limit alcohol consumption.
• Manage chronic conditions (e.g., inflammation) as directed.
• Stay hydrated and follow medical advice for fluid balance.
• Engage in regular, moderate exercise as tolerated.

When to Seek Professional Help

Seek medical attention if you experience persistent symptoms like unexplained swelling, fatigue, shortness of breath, or changes in urination. Prompt evaluation is important for early diagnosis and management of potential complications.

Tips for Medical Coders

Document the specific subtype of amyloidosis when available, as this may impact coding and clinical management. Ensure thorough documentation of organ involvement, diagnostic findings, and underlying causes to support accurate code assignment. Verify that the code aligns with the clinical presentation and any confirmed amyloid protein type.